View All

NASH therapies
Off-label therapies dominate NASH Market Share

NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (NAFLD), is the most common group of conditions in which there is an excess fat accumulation in the liver in people who i...

Find More

Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH)

NASH is defined as the most common form of Nonalcoholic fatty liver disease (NAFLD). The disease is characterized by a spectrum of symptoms including simple steatosis, increased levels of fibrosis, and cirrhosis of the liver. NASH can also result in advanced fibrosis, NASH cirrhosis, and NASH Decompensated Cirrhosi...

Find More

Epidemiology: Fatty Liver Disease

Fatty liver disease is the common form of Non-alcoholic fatty liver disease (NAFLD), whereas very extreme form of NAFLD is termed as Non-alcoholic Steatohepatitis (NASH). NASH is characterized by deposition of fat with 5%-10% of liver weight in liver of people who drink very little or no drinking leading to inflamma...

Find More